Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Dynavax Reports First Quarter 2024 Financial Results
8 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Entry into a Material Definitive Agreement
12 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
2 Nov 23
8-K
Entry into a Material Definitive Agreement
13 Sep 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
S-3ASR
Automatic shelf registration
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
3 Aug 23
8-K
Departure of Directors or Certain Officers
5 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Dynavax Reports First Quarter 2023 Financial Results
2 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
23 Feb 23
CT ORDER
Confidential treatment order
24 Jan 23
8-K
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline Results
9 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Dynavax Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Dynavax Reports Second Quarter 2022 Financial Results
4 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
S-8
Registration of securities for employees
2 Jun 22
8-K
Departure of Directors or Certain Officers
26 May 22
8-K
Dynavax Reports First Quarter 2022 Financial Results
5 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
8-K
Entry into a Material Definitive Agreement
16 Mar 22
Latest ownership filings
3
John L Slebir
5 Apr 24
4
Justin Burgess
19 Mar 24
4
Justin Burgess
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
David F Novack
20 Feb 24
4
Ryan Spencer
20 Feb 24
4
Kelly MacDonald
20 Feb 24
4
Robert Janssen
20 Feb 24
4
Justin Burgess
20 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
4
David F Novack
13 Feb 24
4
Robert Janssen
13 Feb 24
4
Ryan Spencer
13 Feb 24
4
Justin Burgess
13 Feb 24
4
Kelly MacDonald
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4/A
Robert Janssen
7 Feb 24
4
David F Novack
6 Feb 24
4
Ryan Spencer
6 Feb 24
4
Robert Janssen
6 Feb 24
4
Justin Burgess
6 Feb 24
SC 13G/A
STATE STREET CORP
25 Jan 24
SC 13G/A
BlackRock Inc.
19 Jan 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Robert Janssen
8 Jan 24
4
David F Novack
4 Jan 24
144
Notice of proposed sale of securities
4 Jan 24
144
Notice of proposed sale of securities
2 Jan 24
4
David F Novack
5 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
144
Notice of proposed sale of securities
17 Nov 23
4
David F Novack
7 Nov 23
4
David F Novack
3 Nov 23
144
Notice of proposed sale of securities
3 Nov 23
144
Notice of proposed sale of securities
1 Nov 23
144
Notice of proposed sale of securities
24 Oct 23
144
Notice of proposed sale of securities
24 Oct 23
4
Robert Janssen
11 Oct 23
144
Notice of proposed sale of securities
10 Oct 23
144
Notice of proposed sale of securities
10 Oct 23